Bristol-Meyers Squibb said that it will continue to support the evaluation of cabiralizumab in select, ongoing investigator-sponsored trials.
News
Vyndaqel first treatment approved in Europe for ATTR-CM
The decision was based on results from the Phase III ATTR-ACT study.
Sanofi to repurpose SARS vaccine candidate for coronavirus
The company joins J&J, Gilead and GSK in the ranks searching for a vaccine for the global health epidemic.
First patient undergoes Luxturna gene therapy on NHS
Jake Ternet, patient at Moorfields Eye Hospital was the first in the UK to receive the treatment.
MS Society launches ‘first-of-its-kind’ fatigue course
The Society hopes that the new online function will relieve pressure on healthcare professionals, and could result in significant cost savings for the NHS as demand for the face-to-face programme lessens.
New technique developed to ‘listen in’ on cancer cells
Understanding how cells communicate could reveal how tumours are able to evade the immune system and become resistant to treatments.
Scientists create ‘most detailed’ breast cancer map ever
To develop the maps, the team looked within 483 different tumour samples for the presence of 37 key proteins.
Beovu bags EU approval in wet AMD
The drug is the first EC-approved anti-VEGF treatment to demonstrate superior resolution of retinal fluid, compared to Bayer’s Eylea.
Arctoris, Molecule join forces on drug discovery
The news comes as drug discovery rates are declining, the price of bringing a drug to market is increasing, and return on investment (ROI) on R&D is expected to hit 0% in the next few years.
120,000 patients ‘left in the dark’ over cancer treatment
Macmillan Cancer Support has cited “soaring” pressures on the NHS, leaving staff table to provide the appropriate care for patients.
‘Fake news’ could worsen infectious disease ‘epidemic’
The information is as relevant than ever, with Coronavirus still spreading globally.
Subcutaneous Entyvio hits Crohn’s primary endpoint, misses secondary
If approved, the drug could have huge benefits for patients as they could self-administer their therapy from home.
‘Innovative’ PKU treatment launched in UK
PKU is a rare, inherited metabolic disorder that affects approximately 70 babies each year in the UK.
Interim data shows Stelara promise in Crohn’s
Interim data from the Phase IIIb STARDUST study showed that 79% of patients with moderately to severely active Crohn’s disease (CD) achieved clinical response and 67% were in clinical remission.
Mumps at ‘decade high’ in England
Many of the cases in 2019 were seen in the so-called ‘Wakefield cohorts’ – young adults born in the late nineties and early 2000s who missed out on the MMR vaccine when they were children.
